Prelude Therapeutics Inc
NASDAQ:PRLD
Prelude Therapeutics Inc
NASDAQ:PRLD
Price:
4.09 USD
-0.73%
Market Closed
Updated:
May 22, 2024
Section:
Relative Value
There is not enough data to reliably calculate the relative value of PRLD.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
PRLD
Relative Value
Base Case
Not Available
Valuation Multiples
Multiples Across Competitors
PRLD Competitors Multiples
Prelude Therapeutics Inc Competitors
Prelude Therapeutics Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Prelude Therapeutics Inc
NASDAQ:PRLD
|
224.6m USD | 0 | -1.8 | -0.2 | -0.2 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
287.7B USD | 5.3 | 48.4 | 13.5 | 20.9 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
168.9B USD | 5.7 | 44.9 | 18.9 | 31.1 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
114.2B USD | 11.2 | 28.4 | 23.8 | 24.9 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
109.5B USD | 8.4 | 28.4 | 23 | 25.5 | |
| AU |
|
CSL Ltd
ASX:CSL
|
134.1B AUD | 6.3 | 36.2 | 21.9 | 27.1 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
83.8B USD | 3.1 | 173.2 | 8.8 | 11.5 | |
| US |
|
Moderna Inc
NASDAQ:MRNA
|
55B USD | 10.7 | -9.2 | -10.3 | -9.2 | |
| US |
|
Seagen Inc
NASDAQ:SGEN
|
43.1B USD | 18.8 | -57.5 | -61.9 | -55.8 | |
| US |
|
Biogen Inc
NASDAQ:BIIB
|
33.2B USD | 3.4 | 28.4 | 14.5 | 18.1 | |
| KR |
|
Celltrion Inc
KRX:068270
|
38.6T KRW | 17.7 | 72 | 44.1 | 60.7 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
You don't have any saved screeners yet
